Cascadian Therapeutics, Inc.
Cascadian Therapeutics, Inc. (CASC): 2 pipeline candidates · ~16 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
15.7 months
0% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for Cascadian Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$16.8M
Quarterly Burn
$17.1M
Runway
15.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| casc-578 | Preclinical |
| tigit antibody | Preclinical |
Frequently asked questions
How many drug candidates are in Cascadian Therapeutics, Inc.'s pipeline?
Cascadian Therapeutics, Inc. (CASC) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cascadian Therapeutics, Inc.'s lead drug candidate?
Cascadian Therapeutics, Inc.'s most advanced tracked candidate is casc-578 (Preclinical) for To be determined.
What is Cascadian Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cascadian Therapeutics, Inc. has approximately 15.7 months of cash runway.
Who is the CEO of Cascadian Therapeutics, Inc.?
Scott D. Myers is the chief executive officer of Cascadian Therapeutics, Inc. (CASC).
Get the full picture on Cascadian Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.